Clario Executive and Leadership Team

Christopher Fikry, the President & Chief Executive Officer at Clario, directs the company's overarching strategy and operational execution. Fikry guides Clario's mission to deliver leading endpoint technology solutions for clinical trials, ensuring the fusion of scientific expertise and global scale into a comprehensive platform. This leadership role involves driving the company's Trial Anywhere approach, which generates rich clinical evidence across decentralized, hybrid, and site-based trial models. Christopher Fikry's focus remains on empowering pharmaceutical, biotechnology, and medical device partners to accelerate the transformation of lives through high-quality clinical evidence. The President & Chief Executive Officer ensures alignment with market demands and regulatory landscapes across North America, Europe, and the Asia Pacific region, leveraging decades of experience in delivering critical clinical data.

Joshua Collins, the Chief Executive Officer & Founder at Clario, established the company's foundational vision for endpoint technology in clinical trials. Collins drives the strategic direction and innovation that underpins Clario's comprehensive platform, designed to support pharmaceutical, biotechnology, and medical device partners. The Chief Executive Officer & Founder's leadership emphasizes the integration of scientific expertise with global operational scale, enabling the generation of robust clinical evidence. Joshua Collins champions the Trial Anywhere methodology, facilitating rich data capture across decentralized, hybrid, and site-based trial models. This executive's ongoing influence ensures Clario's commitment to transforming lives by delivering high-quality clinical evidence, drawing upon extensive experience in the field.

Nate Goldenman, the President & Chief Executive Officer at Clario, spearheads the company's strategic initiatives and executive leadership. Goldenman directs Clario's commitment to providing advanced endpoint technology solutions essential for clinical trials, integrating scientific rigor with expansive global capabilities. The President & Chief Executive Officer's vision supports partners in the pharmaceutical, biotechnology, and medical device sectors, enabling them to accelerate therapeutic development. Nate Goldenman oversees the execution of the Trial Anywhere approach, ensuring the generation of high-quality clinical evidence across various trial modalities, including decentralized and hybrid models. This leadership ensures Clario's continued impact on transforming lives through decades of experience in delivering reliable clinical data.

Alexander Brito, the Chief Financial Officer, Rei Bookkeeping & Fractional Services at Clario, directs the company's financial strategy and fiscal management. Brito oversees all financial operations, ensuring robust fiscal health and strategic resource allocation to support Clario's endpoint technology solutions for clinical trials. The Chief Financial Officer, Rei Bookkeeping & Fractional Services' role involves managing financial planning, analysis, and reporting, crucial for the company's global scale and scientific endeavors. Alexander Brito ensures that financial frameworks effectively support the Trial Anywhere approach and the generation of high-quality clinical evidence across diverse trial models. This executive's financial acumen is vital for empowering pharmaceutical, biotechnology, and medical device partners and driving the company's mission to transform lives.

Nayan Nanavati, the Chief Operating Officer at Clario, manages the company's extensive operational framework and global execution. Nanavati oversees the day-to-day functions that support Clario's endpoint technology solutions for clinical trials, ensuring seamless integration of scientific expertise and global scale. The Chief Operating Officer's responsibilities include optimizing the delivery of the Trial Anywhere approach, which facilitates the collection of rich clinical evidence across decentralized, hybrid, and site-based trial models. Nayan Nanavati ensures operational efficiency and quality across North America, Europe, and the Asia Pacific region, supporting pharmaceutical, biotechnology, and medical device partners. This executive's leadership drives the company's ability to transform lives through reliable clinical evidence.

Angelo Stortini, the Chief Operating Officer & Senior VP at Clario, leads critical operational functions and strategic oversight. Stortini manages the execution of Clario's endpoint technology solutions for clinical trials, ensuring the seamless fusion of scientific expertise and global scale. The Chief Operating Officer & Senior VP's responsibilities encompass driving operational excellence across the company's platform, supporting pharmaceutical, biotechnology, and medical device partners. Angelo Stortini plays a key role in advancing the Trial Anywhere approach, facilitating the generation of rich clinical evidence across decentralized, hybrid, and site-based trial models. This executive's leadership ensures the delivery of high-quality clinical evidence, contributing significantly to transforming lives through decades of operational experience.

Matthew Borer, the Director - Strategic Chief Revenue Officer Partnerships at Clario, drives revenue growth through strategic alliances and partnership development. Borer focuses on cultivating key relationships that enhance Clario's market presence and expand the reach of its endpoint technology solutions for clinical trials. The Director - Strategic Chief Revenue Officer Partnerships' role involves identifying and securing collaborations that align with the company's mission of fusing scientific expertise and global scale. Matthew Borer ensures these partnerships contribute to the successful implementation of the Trial Anywhere approach, generating rich clinical evidence across diverse trial models. This executive's strategic focus supports pharmaceutical, biotechnology, and medical device partners in transforming lives through high-quality clinical evidence.

Todd Rudo, the Chief Medical Officer at Clario, provides essential medical and scientific leadership for the company's clinical trial technology solutions. Rudo guides the integration of deep scientific expertise into Clario's comprehensive endpoint platform, ensuring the highest standards of clinical evidence generation. The Chief Medical Officer's responsibilities include overseeing the medical strategy that supports pharmaceutical, biotechnology, and medical device partners, particularly within the Trial Anywhere framework. Todd Rudo ensures that the data generated across decentralized, hybrid, and site-based trial models is scientifically sound and clinically relevant. This executive's medical insight is crucial for transforming lives by delivering high-quality, reliable clinical evidence.

Eric Schwartz, the Executive Vice President & Chief Legal Officer at Clario, directs the company's comprehensive legal strategy and compliance framework. Schwartz ensures that all operations, particularly those involving endpoint technology solutions for clinical trials, adhere to global regulatory standards and ethical guidelines. The Executive Vice President & Chief Legal Officer's role is critical in navigating the complex legal landscapes across North America, Europe, and the Asia Pacific region. Eric Schwartz provides legal counsel that supports the company's fusion of scientific expertise and global scale, safeguarding the integrity of the Trial Anywhere approach. This executive's legal oversight is fundamental to protecting partners and ensuring the reliable generation of clinical evidence.

Fabian Chen, the Vice President and Deputy Chief Medical Officer, Cardiology at Clario, provides specialized medical leadership within the cardiovascular domain for clinical trials. Chen focuses on ensuring the scientific rigor and clinical relevance of endpoint technology solutions, particularly for cardiology-focused studies. The Vice President and Deputy Chief Medical Officer, Cardiology's expertise supports the generation of high-quality clinical evidence, aligning with Clario's mission to fuse scientific expertise and global scale. Fabian Chen contributes to the effective implementation of the Trial Anywhere approach, ensuring accurate data capture across diverse trial models for cardiovascular research. This executive's medical acumen is vital for advancing patient care through reliable clinical evidence.